News

BioPharma Dive9h
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...
STAT3d
At ASCO 2025, attendees see reason for hope, despite worries
The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...
Fierce Biotech13d
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...
BioPharma Dive1d
AstraZeneca drug could help keep a common breast cancer at bay
Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...
STAT2d
ASCO day 2: A tragic paradox, Gilead updates, and lots of Pfizer news
This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.
Pfizer’s Braftovi Doubles Survival in Advanced Colorectal Cancer
A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...
The New York Times1y
Tornado at Pfizer Warehouse Likely to Worsen Shortage of Surgical Drugs
A tornado that ripped apart a vast Pfizer drug warehouse in North Carolina ... Last Time This Happened: Cancer drug shortage threatened patient care. This disaster struck as the last drug ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...